RSS feed

Press Room

The Boards of Kowa Research Europe Ltd. (KRE) and Kowa Pharmaceutical Europe C. Ltd. (KPE) are pleased to announce the appointment of Dr Ralph Zaat as the President of the Companies, with effect from the 1st February 2016.

02 Feb 2016

The Boards of Kowa Research Europe Ltd. (KRE) and Kowa Pharmaceutical Europe C. Ltd. (KPE) are pleased to announce the appointment of Dr Ralph Zaat as the President of the Companies, with effect from the 1st February 2016.

More

The Board of Directors announce that Gilles Picard will step down as president and member of the Board of Directors, effective 14 April 2015.

17 Apr 2015

The Board of Directors announce that Gilles Picard will step down as president and member of the Board of Directors, effective 14 April 2015. Board of Directors will serve as the interim president while the board conducts a search for a new president.

More

We are attending the European Society of Cataract and Refractive Surgeons (ESCRS) Congress. Come and visit us at our booth.

5-9 Sept 2015

ESCRS, 5-9 September 2015, Barcelona. European Society of Cataract and Refractive Surgeons (ESCRS) Congress 2015

More

We are attending the Internationaler Kongress der Deutschen Ophthalmochirurgen (DOC) 2015

11-13 June 2015

DOC, 11-13 June 2015, Leipzig. Internationaler Kongress der Deutschen Ophthalmochirurgen (DOC) 2015

More

We are supporting wetlabs to be held at Augenarztliche Akademie Deutschland (AAD) 2015

17-21 March 2015

AAD, 17-21 March 2015, Düsseldorf. We are supporting wetlabs to be held at Augenarztliche Akademie Deutschland (AAD) 2015.

More

Spanish experts offer guidence on the use of statins in people at risk of developing diabetes mellitus

29 May 2014

New guidance published in atherosclerosis supplements

More

Kowa Research Europe Ltd. and Kowa Pharmaceutical Europe Co. Ltd. President Resigns, Board Appoints Successor

15 Nov 2013

The KRE and KPE Boards have appointed Gilles J. Picard

More

LDL-C Lowering of Pitavastatin Equivalent to Other Statins but Effect on HDL-C and Triglycerides Superior, Review of Primary Publications Shows.

12 Jun 2012

Two papers published in the European Journal of Preventive Cardiology

More

Pitavastatin consistently demonstrates sustained increases in HDL-C and offers atheroprotective benefits.

27 Jun 2011

Pitavastatin consistently demonstrates sustained increases in HDL-C

More

New European Atherosclerosis Society's guidance highlights need to target triglycerides and high-density lipoproteins to reduce cardiovascular disease risk.

27 Jun 2011

New European Atherosclerosis Society's guidance highlights need to target triglycerides

More

Livazo® (pitavastatin), a new potent statin with beneficial effects on lipid fractions associated with heart disease, launches in Spain

03 May 2011

Livazo® (pitavastatin), a new potent statin with beneficial effects on lipid fractions

More

European / MENA approvals

31 Mar 2011

European / MENA approvals and Launch : March saw the first launch of Livazo in the region

More

Kowa announces first EU marketing authorisation for pitavastatin granted in the UK

17 Aug 2010

Statin licenced to treat patients with primary hypercholesterolaemia or combined dyslipidemia

More

Pitavastatin has achieved a positive outcome from the UK Regulatory

20 Jul 2010

Kowa are delighted to announce the completion of the decentralized regulatory procedure

More

Kowa Company, Ltd. grants Abbott exclusive rights to market pitavastatin calcium, in Australia and New Zealand

28 Jun 2010

Kowa Company, Ltd. grants Abbott exclusive rights

More

Pitavastatin demonstrates sustained efficacy, tolerability and LDL-C target attainment over 52 weeks

20 Apr 2010

Pitavastatin represents effective long-term treatment option

More

Study Demonstrates LIVALO® Is an Efficacious Treatment for Achieving Lipid Goals

22 Oct 2009

Study Demonstrates LIVALO® Is an Efficacious Treatment for Achieving Lipid Goals

More

New Phase III data published today in “Current Medical Research and Opinion”

22 Oct 2009

New Phase III data published today in “Current Medical Research and Opinion”

More

Pitavastatin demonstrates no significant drug-to-drug interaction when administered with CYP3A4 inhibitors

25 Aug 2009

Pitavastatin demonstrates no significant drug-to-drug interaction

More

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

16 Jun 2009

Represents important treatment option for more vulnerable populations

More

Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug Interaction

13 Jun 2009

Study shows Kowa’s novel synthetic statin is safe and well tolerated in combination with warfarin

More

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients Pitavastatin [Europe]

13 Jun 2009

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients [Europe]

More

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients [CANADA]

13 Jun 2009

Pitavastatin represents important treatment option for more vulnerable populations [CANADA F]

More

Kowa Pharmaceuticals America Announces Strategic Divestiture of Diclofenac Assets

14 Apr 2009

KPA has announced plans to divest its unique franchise of diclofenac products

More

Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc. New Company to be Called Kowa Pharmaceuticals America

08 Apr 2008

Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc. New Company

More

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X